EUVIMEDEUVIMED entdecken
Crossref

Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease

Chien-Tai Hong, Chen-Chih Chung, Yi-Chen Hsieh, Lung Chan

BioScience Trends · 2025

DOI: 10.5582/bst.2024.01369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioScience Trends, 2025. Verfasst von Chien-Tai Hong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Parkinson Disease, Extracellular Vesicles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is a progressive neurodegenerative disorder for which reliable blood biomarkers to predict disease progression remain elusive. Plasma extracellular vesicles (EVs) have gained attention as a promising biomarker platform due to their stability and ability to cross the blood-brain barrier. This study explored the potential of EV-cargo proteins, specifically α-synuclein, tau, and β-amyloid, as biomarkers of PD progression. A cohort of 55 people with PD (PwP) and 58 healthy controls (HCs) underwent annual assessments of plasma EV proteins, cognition, and motor symptoms. EVs were isolated and validated using standardized methods, with pathognomonic proteins quantified via immunomagnetic reduction assays. Associations between biomarker changes and clinical symptom progression were analyzed. Over an average of 3.96 visits for PwP and 2.25 visits for HCs, PwP exhibited a distinct pattern of plasma EV protein changes linked to motor symptom progression, particularly in the Unified PD Rating Scale (UPDRS) part II score. Notably, changes in plasma EV α-synuclein levels were significantly correlated with changes in motor and cognitive symptoms, suggesting its central role in disease progression. These findings highlight the potential of plasma EV biomarkers, especially α-synuclein, as indicators of ongoing pathogenesis and as candidates for evaluating α-synuclein-targeted therapies in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseExtracellular VesiclesHumansBiomarkersDisease ProgressionMaleFemalealpha-SynucleinAgedMiddle Agedtau ProteinsAmyloid beta-PeptidesCase-Control Studies

Stichwörter der Autor:innen

canagliflozincype-2 diabetes mellitussodium glucose transporter 2 inhibitorstype-2 diabetes mellitus

Substanzen

Biomarkersalpha-Synucleintau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
  • Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.
  • Ph.D in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Zitieren

APA

Hong, C. T., Chung, C. C., Hsieh, Y. C., & Chan, L. (2025). Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease. BioScience Trends. https://doi.org/10.5582/bst.2024.01369

Vancouver

Hong CT, Chung CC, Hsieh YC, Chan L. Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease. BioScience Trends. 2025. doi:10.5582/bst.2024.01369

BibTeX
@article{Hong2025,
  author = {Hong, Chien-Tai and Chung, Chen-Chih and Hsieh, Yi-Chen and Chan, Lung},
  title = {Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease},
  journal = {BioScience Trends},
  year = {2025},
  doi = {10.5582/bst.2024.01369}
}
Kostenlos starten →